Drugs / FB-1603
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06478719 | Jun 2024 → Jun 2028 expected | hepatocellular carcinoma | Febico Biomedical Corp. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FB-1603 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06478719 ↗ |
| Route | Oral | “The investigational drugs should be taken orally about 10 minutes before the breakfast, lunch, and dinner” NCT06478719 ↗ |